Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2023-12-19 Director's Dealing
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2023-12-19 Korean
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory notice from Qriom regarding the setting of a record date and shareholder register closure period for the purpose of a bonus issue (free share issuance). It does not contain full financial statements or proxy materials, but rather serves as a specific regulatory disclosure regarding corporate action. Given it does not fit into specific categories like dividend announcements or director dealings, it falls under the general regulatory filing category.
2023-12-19 Korean
주요사항보고서(자본으로인정되는채무증권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). It details the board's decision to issue debt securities (convertible bonds) that qualify as capital. This falls under the category of capital structure changes and financing activities. Since it is a formal regulatory filing regarding a specific financing event (issuance of bonds), it is classified as a Capital/Financing Update.
2023-12-19 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Qurient Co., Ltd. regarding a decision for a third-party paid-in capital increase (유상증자결정). This document details the issuance of new shares, the purpose of the capital raise, the pricing methodology, and the list of third-party allottees. In the context of Korean corporate filings, this is a standard regulatory disclosure regarding capital changes and share issuance. Therefore, it falls under the 'Share Issue/Capital Change' category.
2023-12-19 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding the issuance of convertible bonds (전환사채권 발행결정). This type of regulatory filing in the Korean market is a standard disclosure for capital structure changes and financing activities. Based on the provided definitions, this falls under 'Capital/Financing Update' (CAP) as it details the terms, purpose, and issuance of debt instruments.
2023-12-19 Korean
[기재정정]주요사항보고서(유무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from a Korean company (Qurient) detailing a correction (정정신고) to a previous filing regarding a capital increase (both paid-in and bonus issues). In the context of Korean corporate filings (DART system), these reports regarding capital changes, share issuance, and amendments to such plans are classified as 'Share Issue/Capital Change' filings.
2023-12-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.